Page last updated: 2024-10-19

niacin and Atheroma

niacin has been researched along with Atheroma in 10 studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Research Excerpts

ExcerptRelevanceReference
"Niacin-treated subjects compared to untreated subjects had significantly less change in mean coronary stenosis (0."6.78Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment ( Brown, BG; Isquith, D; Muñoz, L; Phan, BA; Shadzi, P; Triller, M; Zhao, XQ, 2013)
"Niacin-treated subjects compared to untreated subjects had significantly less change in mean coronary stenosis (0."2.78Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment ( Brown, BG; Isquith, D; Muñoz, L; Phan, BA; Shadzi, P; Triller, M; Zhao, XQ, 2013)
"Dalcetrapib has been well tolerated at the 600-mg dose."2.48An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. ( Arsenault, BJ; Brodeur, MR; Rhainds, D; Tardif, JC, 2012)
" In conclusion, these data suggest that long-term administration of nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions, which are independent of its lipid-modifying actions."1.37Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities. ( Albrecht, C; Bea, F; Blessing, E; Buttler, A; Holzhäuser, E; Katus, HA; Preusch, MR; Zhou, Q, 2011)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19901 (10.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (90.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chai, JT1
Digby, JE1
Ruparelia, N1
Jefferson, A1
Handa, A1
Choudhury, RP1
Sibley, CT1
Vavere, AL1
Gottlieb, I1
Cox, C1
Matheson, M1
Spooner, A1
Godoy, G1
Fernandes, V1
Wasserman, BA1
Bluemke, DA1
Lima, JA1
Lim, GB1
Ylä-Herttuala, S1
Bentzon, JF1
Daemen, M1
Falk, E1
Garcia-Garcia, HM1
Herrmann, J1
Hoefer, I1
Jauhiainen, S1
Jukema, JW1
Krams, R1
Kwak, BR1
Marx, N1
Naruszewicz, M1
Newby, A1
Pasterkamp, G1
Serruys, PW1
Waltenberger, J1
Weber, C1
Tokgözoglu, L1
Kuge, Y1
Takai, N1
Ogawa, Y1
Temma, T1
Zhao, Y1
Nishigori, K1
Ishino, S1
Kamihashi, J1
Kiyono, Y1
Shiomi, M1
Saji, H1
Holzhäuser, E1
Albrecht, C1
Zhou, Q1
Buttler, A1
Preusch, MR1
Blessing, E1
Katus, HA1
Bea, F1
Rhainds, D1
Arsenault, BJ1
Brodeur, MR1
Tardif, JC1
Strack, AM1
Carballo-Jane, E1
Wang, SP1
Xue, J1
Ping, X1
McNamara, LA1
Thankappan, A1
Price, O1
Wolff, M1
Wu, TJ1
Kawka, D1
Mariano, M1
Burton, C1
Chang, CH1
Chen, J1
Menke, J1
Luell, S1
Zycband, EI1
Tong, X1
Raubertas, R1
Sparrow, CP1
Hubbard, B1
Woods, J1
O'Neill, G1
Waters, MG1
Sitlani, A1
Phan, BA1
Muñoz, L1
Shadzi, P1
Isquith, D1
Triller, M1
Brown, BG1
Zhao, XQ1
HUNTER, JD1
WONG, LC1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The RIGHT Study: Risk Stratification With Image Guidance of HMG Coa Reductase Inhibitor Therapy[NCT01212900]Phase 4230 participants (Actual)Interventional2010-09-30Completed
Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy[NCT00715273]Phase 4217 participants (Actual)Interventional2001-05-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Mean of Wall Volume of Internal Carotid Arteries

Wall volume of internal carotid arteries was measured using magnetic resonance imaging. Participants will undergo 2D and 3D carotid MRI using a 3 Tesla scanner and surface carotid coils. Participants with mild or no atherosclerosis, defined as the lowest tertile of wall volume, will have statin therapy adjusted to a target range of 100-130 mg/dL. Participants in the middle tertile will receive statin therapy adjusted to achieve a target LDL 70-100 mg/dL. Participants with the most severe atherosclerosis will receive statin therapy to an LDL target between 40 and 70 mg/dL. Participants in the Standard arm will have lipid sub-fraction targets determined according to estimated 10 year cardiovascular risk, as per standard NCEP guidelines. (NCT01212900)
Timeframe: 24 months

InterventionOther - mm^3 ( cubic millimeter ) (Mean)
Imaging-3.52
Standard-5.91

Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI

"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3

Interventionmm^3/year (Mean)
1 - Single Therapy Group-4.6
2 - Double Therapy Group-15.1
3 - Triple Therapy Group-9.4

Annualized LRNC and Wall Volume Changes in Carotid Plaque Composition, as Assessed by MRI

"The primary endpoint of this study is carotid plaque lipid composition identified by MRI. The determination of plaque lipid content for each carotid artery will be performed using the automated interactive system. These measurements will be performed from the MRI scans at four time points blinded to time sequence of MRI examinations, patient treatment, lipid levels and clinical course.~Volume Measurements: Contours were placed around the lumen, outer-wall boundaries, and plaque features of carotid artery. (Arterial wall area) = (outer-wall area) - (lumen area). Volume calculated as: area x 2 mm (slice thickness). Tissue volume/wall volume x (100%) is presented as percentage. Annualized change presented mm^3/year (for volume) and as percentage change/year." (NCT00715273)
Timeframe: Measured at Years 1, 2, and 3

,,
Interventionpercentage change/year (Mean)
LRNC changeWall Volume change
1 - Single Therapy Group-1.6-0.6
2 - Double Therapy Group-3.6-1.4
3 - Triple Therapy Group-2.8-1.2

Composite of Cardiovascular Endpoints: Number of Participants With Cardiovascular Disease Death, Non-fatal Heart Attack, Stroke, and Worsening Ischemia Requiring Medical Interventions

Any cardiovascular events such as death from any cause, nonfatal myocardial infarction, stroke, and revascularization procedures (PCI or CABG) due to unstable ischemia will be recorded and verified. (NCT00715273)
Timeframe: Measured at Years 3, 4, and 5

,,
InterventionParticipants (Count of Participants)
Composite Measured at Year 3Composite Measured at Year 4 (cumulative)Composite Measured at Year 5 (cumulative)
1 - Single Therapy Group679
2 - Double Therapy Group61111
3 - Triple Therapy Group799

Reviews

1 review available for niacin and Atheroma

ArticleYear
An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
    Future cardiology, 2012, Volume: 8, Issue:4

    Topics: Amides; Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol Ester Transfer Prote

2012

Trials

2 trials available for niacin and Atheroma

ArticleYear
MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study.
    Heart (British Cardiac Society), 2013, Volume: 99, Issue:22

    Topics: Aged; Carotid Artery Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydro

2013
Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dl): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment
    The American journal of cardiology, 2013, Feb-01, Volume: 111, Issue:3

    Topics: Blood Glucose; Carotid Stenosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary

2013

Other Studies

7 other studies available for niacin and Atheroma

ArticleYear
Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells.
    PloS one, 2013, Volume: 8, Issue:5

    Topics: ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Bin

2013
Atherosclerosis: Addition of niacin to optimal statin therapy does not affect plaque regression.
    Nature reviews. Cardiology, 2013, Volume: 10, Issue:10

    Topics: Carotid Artery Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Re

2013
Stabilization of atherosclerotic plaques: an update.
    European heart journal, 2013, Volume: 34, Issue:42

    Topics: Antihypertensive Agents; Apolipoprotein B-100; Blood Platelets; CCR5 Receptor Antagonists; Chemokine

2013
Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques.
    European journal of nuclear medicine and molecular imaging, 2010, Volume: 37, Issue:11

    Topics: Animals; Antibodies, Monoclonal; Humans; Immunoglobulin G; Male; Matrix Metalloproteinase 14; Molecu

2010
Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities.
    Journal of cardiovascular pharmacology, 2011, Volume: 57, Issue:4

    Topics: Animals; Anti-Inflammatory Agents; Aorta, Thoracic; Apolipoproteins E; Brachiocephalic Trunk; Female

2011
Nicotinic acid and DP1 blockade: studies in mouse models of atherosclerosis.
    Journal of lipid research, 2013, Volume: 54, Issue:1

    Topics: Animals; Aorta; Apolipoproteins E; Cholesterol; Drug Interactions; Endpoint Determination; Female; G

2013
Nicotinic acid effect on cockerels. Cholesterol and atheroma lesions.
    Archives of pathology, 1961, Volume: 72

    Topics: Animals; Arteriosclerosis; Chickens; Cholesterol; Humans; Male; Niacin; Nicotinic Acids; Plaque, Ath

1961
chemdatabank.com